Companies / REGN vs ZTS
REGN vs ZTS: Regeneron Pharmaceuticals and Zoetis
Regeneron Pharmaceuticals (REGN) reported $14.3B in revenue against a 31.4% net margin, while Zoetis (ZTS) reported $9.5B at a 28.2% net margin, most recently.
| Metric | REGN | ZTS |
|---|---|---|
| Revenue | $14.3B | $9.5B |
| Net Income | $4.5B | $2.7B |
| Gross Margin | — | 71.8% |
| Operating Margin | 24.9% | — |
| EPS (Diluted) | $41.48 | $6.02 |
| Free Cash Flow | $4.1B | $2.3B |
| Total Debt | $2.7B | $9.0B |
| P/E Ratio | 18.6× | 20.9× |
| P/B Ratio | n/m | 16.1× |
| Stock Price | $910.75 | $82.13 |
Free: last 5 years
| Fiscal year | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| ZTS Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |